Texas Pharmacy Shut Out of Controlled Substances by DEA
Published Date: 4/1/2025
Notice
Summary
Baijes Bissonnet Pharmacy in Texas tried to get a DEA registration but got denied because they filled risky prescriptions without fixing warning signs. They missed the deadline to ask for a hearing, so the DEA’s decision stands. This means the pharmacy can’t legally handle certain controlled medicines, affecting their business and customers right away.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
Baijes Bissonnet Pharmacy Registration Denied
Baijes Bissonnet Pharmacy's application for a DEA Certificate of Registration (Control No. W22147152A) is denied. The denial is effective May 1, 2025, and the Order also denies any other pending DEA registration application by Baijes Bissonnet Pharmacy in Texas.
Patients Lose Controlled-Med Access At Pharmacy
Customers who rely on Baijes Bissonnet Pharmacy in Stafford, Texas may no longer be able to obtain controlled-substance prescriptions there after May 1, 2025 because the pharmacy's DEA registration application was denied. The Order follows findings that the pharmacy repeatedly filled controlled-substance prescriptions with multiple red flags from at least March 2021 through August 2022.
Filling Red-Flag Prescriptions Risks Registration
The DEA found that repeatedly filling controlled-substance prescriptions that contained red flags (for example: pattern prescribing, cash payments, long-distance patients, and drug ‘cocktails’) supports denial of DEA registration. The Agency relied on factual findings including that 492 of 575 controlled-substance prescriptions (85%) were paid in cash and that 42 prescriptions to six individuals were essentially identical.
Missing Hearing Deadline Can Cause Default
The DEA deemed the applicant in default because it did not file a timely hearing request after being served the Order to Show Cause on December 19, 2023; the 30-day deadline for a hearing request ran to January 18, 2024. A default is deemed a waiver of the right to a hearing and an admission of the OSC allegations, which supported the Agency's request for final action.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-05526, Phong H. Tran, M.D.; Decision and Order
The DEA has officially denied Dr. Phong H. Tran’s application to register for handling controlled substances in California because he’s excluded from federal health programs and lacks state permission. This means Dr. Tran can’t legally prescribe or manage certain drugs, impacting his medical practice and patients. The decision is final as of April 1, 2025, and no appeals were filed.
Next: 2025-05528, Mary Massullo, D.O.; Decision and Order
Mary Massullo, D.O., lost her license to handle controlled substances because she no longer has permission from Ohio, where she’s registered. She didn’t ask for a hearing, so the DEA decided to revoke her registration officially. This means she can’t legally work with controlled drugs anymore, and her registration expired on January 31, 2025.